NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D.,
Stemline’s CEO, will be presenting at two upcoming investor conferences:
- The Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 8:00 AM ET, being held at the
InterContinental New York Barclay Hotel, New York City.
- The Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 8:30 AM ET, being held at the Sofitel New
York, New York City.
A webcast of each presentation can be viewed on the company's website at www.stemline.com.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics for difficult to treat
cancers. Stemline is developing three clinical stage product candidates: SL-401, SL-801, and SL-701. SL-401 is a targeted therapy
directed to the interleukin-3 receptor (CD123), a cell surface receptor expressed on a variety of malignancies including blastic
plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive, lethal malignancy of unmet medical need, with no approved
therapies. SL-401 was granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BPDCN. A pivotal Phase 2
trial with SL-401 in BPDCN has completed enrollment. An additional cohort is currently enrolling BPDCN patients to ensure continued
access to SL-401. Additional Phase 1/2 trials with SL-401, including as a single agent or in combination with other agents, are
ongoing in patients with other malignancies including myeloproliferative neoplasms (MPN) (focused on chronic myelomonocytic
leukemia [CMML] and myelofibrosis [MF]), acute myeloid leukemia (AML), and multiple myeloma. A Phase 1 trial of SL-801, a novel
oral small molecule reversible XPO1 inhibitor, is enrolling patients with advanced solid tumors. Results presented at the European
Society of Medical Oncology (ESMO) Annual Congress in September 2017 included dose escalation data of SL-801 through 6 dosing
cohorts without dose limiting toxicity coupled with a 37.5% rate of stable disease, including several cases of tumor shrinkage in
heavily pretreated patients. The ideal therapeutic dose of SL-801 has not yet been determined and dose escalation/schedule
optimization continues. A Phase 2 trial of SL-701, an immunotherapeutic, has completed dosing of patients with second-line
glioblastoma and patients are being followed for outcomes including survival.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the
success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation,
institutional review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data
observed, and input from regulatory authorities including the risk that the FDA or other ex-U.S. national drug authority ultimately
does not approve any of our product candidates; our plans to develop and commercialize our product candidates; market acceptance of
our products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain
intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party
manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors
identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set
forth in this press release speak only as of the date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
